INDUSTRY NEWS

RWE-67-ISPOR-on-RWD-Advantages

ISPOR on RWD Advantages

  • Rapid and effective data generation increases value for the study sponsor.
  • Larger groups allow for longitudinally tracking of patient cohorts and sub-population analyses
  • Real world studies demonstrate real-world practices and behaviours.

SVMPharma, driving the outcomes that matter with RWE studies leading to positive HTA submissions and value based outcomes. Why be limited with small study populations, when SVMPharma are able to deliver studies with over 1000 patients?

Click here to read the source article

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com